A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: GSK3326595
Sponsor: Ottawa Hospital Research Institute
Collaborators: Ontario Institute for Cancer Research|GlaxoSmithKline|London Regional Cancer Program, Canada|Hamilton Health Sciences Corporation